All
FDA Approves Lorbrena for Metastatic Non-Small Cell Lung Cancer Subtype
November 3rd 2018The Food and Drug Administration (FDA) granted accelerated approval to Lorbrena (lorlatinib) for the treatment of patients with ALK-positive, metastatic non-small cell lung cancer (NSCLC) who progressed on one or more ALK tyrosine kinase inhibitor (TKI), according to Pfizer, the drug’s manufacturer.
Maintenance Lynparza Improves PFS for Ovarian Cancer
October 30th 2018The PARP inhibitor Lynparza (olaparib) significantly improved progression-free survival (PFS) as frontline maintenance therapy for women with BRCA-positive advanced ovarian cancer, according to findings from the randomized phase 3 SOLO-1 trial presented at the 2018 ESMO Congress.
FDA Grants Priority Review to Jakafi for Acute Graft-Versus-Host-Disease
October 26th 2018The Food and Drug Administration has granted a priority review to the supplemental new drug application for Jakafi (ruxolitinib) to treat patients with acute graft-versus-host-disease (GVHD) who have had an inadequate response to corticosteroids.
FDA Grants Priority Review to Lonsurf for Gastric Adenocarcinoma
October 26th 2018The Food and Drug Administration (FDA) has granted a priority review to a supplemental new drug application for Lonsurf (TAS-102; trifluridine/tipiracil) for use in previously treated patients with advanced or metastatic gastric adenocarcinoma, including cancer of the gastroesophageal junction.
Replacing Agent in R-CHOP Regimen Improves Survival in Mantle Cell Lymphoma
October 26th 2018The replacement of vincristine with Velcade (bortezomib) in the R-CHOP regimen for the treatment of transplantation-ineligible patients with newly diagnosed mantle cell lymphoma improved overall survival in a final analysis of the LYM-3002 trial.
Encouraging Preliminary Results in Myelofibrosis Trial Lead to Enhancements in Phase 2
October 26th 2018After seeing encouraging phase 1 results, the phase 2 portion of a clinical trial currently evaluating the efficacy of the BET inhibitor CPI-0610 in patients with myelofibrosis has been enhanced and expanded.